Table 6

PRO EQ-5D and QLQ-C30subscale scores at baselineand safety follow-up
KRAS PRO analysis set PRO analysis set
WT KRAS (n= 76)a MT KRAS (n= 54)a Overall (n= 137)a
Baseline Safety follow-up Baseline Safety follow-up Baseline Safety follow-up
Mean (SD) EQ-5D subscalescoresb
  Mobility 1.13 (0.34) 1.17 (0.38) 1.13 (0.34) 1.12 (0.42) 1.12 (0.33) 1.16 (0.41)
  Self care 1.05 (0.23) 1.14 (0.35) 1.13 (0.44) 1.15 (0.51) 1.08 (0.32) 1.15 (0.43)
  Usual activities 1.29 (0.56) 1.39 (0.60) 1.35 (0.59) 1.34 (0.65) 1.30 (0.56) 1.38 (0.62)
  Pain/discomfort 1.45 (0.58) 1.53 (0.56) 1.53 (0.58) 1.46 (0.56) 1.46 (0.57) 1.51 (0.56)
  Anxiety/depression 1.26 (0.50) 1.25 (0.44) 1.39 (0.49) 1.33 (0.48) 1.31 (0.49) 1.30 (0.46)
Mean (SD) QLQ-C30 functioningscoresc
  Physical 71.7 (20.1) 71.3 (20.5)d 71.9 (19.6) 78.6 (10.5)d 72.5 (19.8) 74.3 (18.2)d
  Role 26.1 (33.4) 30.0 (33.3) 32.1 (35.0) 28.8 (29.8) 27.4 (33.7) 30.3 (31.2)
  Cognitive 10.2 (17.7) 13.3 (19.7) 13.6 (22.7) 14.1 (18.2) 11.0 (19.6) 14.4 (19.6)
  Emotional 24.3 (23.1) 22.1 (20.0) 26.5 (22.9) 14.9 (19.0) 24.6 (22.6) 19.8 (20.5)
  Social 25.8 (33.4) 25.7 (27.8) 23.5 (32.6) 16.7 (21.2) 23.6 (32.5) 22.4 (24.9)
Mean (SD) QLQ-C30 symptomscorese
  Fatigue 29.0 (27.8) 31.9 (28.3) 35.4 (31.6) 31.3 (22.6) 31.4 (28.8) 32.3 (26.0)
  Pain 19.1 (27.4) 22.9 (27.4) 25.3 (29.6) 19.3 (26.1) 21.2 (27.9) 21.6 (26.6)
  Nausea/vomiting 3.3 (10.6) 7.6 (14.2) 8.6 (19.1) 10.6 (19.9) 5.3 (14.6) 8.6 (16.8)
Mean (SD) QLQ-C30 single-itemscorese
  Dyspnoea 17.1 (27.5) 21.0 (28.1) 23.5 (30.8) 21.2 (21.8) 19.2 (28.5) 21.3 (26.4)
  Insomnia 29.8 (35.8) 23.8 (28.7) 28.4 (32.0) 23.2 (27.0) 29.4 (34.2) 25.0 (28.9)
  Appetite loss 18.9 (31.0) 15.2 (30.6) 25.9 (35.3) 15.2 (27.8) 20.7 (32.4) 14.4 (28.4)
  Constipation 13.3 (23.2) 4.8 (14.3) 14.2 (25.6) 12.1 (23.3) 14.0 (23.8) 9.7 (22.0)
  Diarrhoea 20.7 (30.6) 12.4 (23.0) 19.1 (30.8) 22.2 (27.2) 19.5 (30.0) 18.1 (25.6)
  Financial impact 8.1 (20.5) 7.6 (18.2) 6.8 (17.6) 11.5 (26.2) 7.2 (18.8) 9.4 (22.0)

aActual ‘n’ number may differ according to subscale item and time point (data from fewer patients were available at safety follow-up vs. baseline); bHigher scores indicate a better level of functioning of a greater degree of symptomology depending on subscale; cA higher score indicates a better level of functioning/health; cA higher score indicates a better level of functioning/health; dData not available at safety follow-up, data reported at week 48 instead; eA higher score indicates a greater degree of symptomology.

Thaler et al.

Thaler et al. BMC Cancer 2012 12:438   doi:10.1186/1471-2407-12-438

Open Data